A Malfroot
Overview
Explore the profile of A Malfroot including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
647
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hanssens L, Duchateau J, Namane S, Malfroot A, Knoop C, Casimir G
Prostaglandins Leukot Essent Fatty Acids
. 2020 Feb;
158:102060.
PMID: 32044180
Lung transplantation is assumed to normalize essential fatty acid (EFA) profile in the plasma, described as abnormal in patients with cystic fibrosis (CF). This study sought to evaluate the EFA...
2.
Dodemont M, Argudin M, Willekens J, Vanderhelst E, Pierard D, Miendje Deyi V, et al.
J Cyst Fibros
. 2018 May;
18(1):86-93.
PMID: 29805051
Background: This study aims to determine the prevalence and characteristics of Staphylococcus aureus in Belgian cystic fibrosis (CF) patients. Methods: Non-duplicate respiratory samples from 510 CF-patients (2012-2013) were examined. One...
3.
De Wachter E, Thomas M, Wanyama S, Seneca S, Malfroot A
Orphanet J Rare Dis
. 2017 Aug;
12(1):142.
PMID: 28830496
Background: CFTR2 provides clinical and functional information of the most common CFTR-mutations. Rare mutations (RMs) occur in only a few patients with limited reported clinical data. Their role in CF-disease...
4.
Inhaled dry powder mannitol in children with cystic fibrosis: A randomised efficacy and safety trial
De Boeck K, Haarman E, Hull J, Lands L, Moeller A, Munck A, et al.
J Cyst Fibros
. 2017 Mar;
16(3):380-387.
PMID: 28258928
Introduction: Inhaled mannitol has beneficial effects on lung function, mucociliary clearance, quality of life and sputum properties. This trial examined the efficacy of inhaled mannitol in children with cystic fibrosis...
5.
Hanssens L, Thiebaut I, Lefevre N, Malfroot A, Knoop C, Duchateau J, et al.
Prostaglandins Leukot Essent Fatty Acids
. 2016 May;
108:45-50.
PMID: 27154364
Effectiveness of omega-3 supplementation in cystic fibrosis (CF) remains controversial. This study sought to evaluate clinical status, exercise tolerance, inflammatory parameters, and erythrocyte fatty acid profile after 1 year of...
6.
De Wachter E, De Schutter I, Meulemans A, Buyl R, Malfroot A
J Cyst Fibros
. 2015 Jul;
15(1):60-6.
PMID: 26190830
Background: According to European and US protocols, two nasal potential difference (NPD) measurement methods are considered acceptable, although they have not been formally compared: subcutaneous agar-filled needle with calomel (Ndl)...
7.
Vollebregt M, Malfroot A, De Raedemaecker M, van der Burg M, van der Werff Ten Bosch J
Case Reports Immunol
. 2015 Jun;
2015:137368.
PMID: 26064716
Rapadilino syndrome is a genetic disease characterized by a characteristic clinical tableau. It is caused by mutations in RECQL4 gene. Immunodeficiency is not described as a classical feature of the...
8.
Vanderhelst E, De Wachter E, Willekens J, Schuermans D, Vincken W, Malfroot A, et al.
Acta Clin Belg
. 2014 Sep;
70(1):30-3.
PMID: 25253536
Effective microbiogical eradication of methicillin-resistant Staphylococcus aureus (MRSA) in patients with cystic fibrosis (CF) can be obtained, but its effect is not always clear-cut in terms of spirometric indices. The...
9.
Boudewyns A, Antunes J, Bernheim N, Claes J, De Dooy J, De Leenheer E, et al.
B-ENT
. 2013 Feb;
8 Suppl 19:135-66.
PMID: 23431617
Treatment for chronic inflammatory conditions in children should take into account the specific pathophysiological and clinical processes underlying these disorders. These guidelines provide a framework for both the medical and...
10.
Vanderhelst E, De Meirleir L, Verbanck S, Pierard D, Vincken W, Malfroot A
J Cyst Fibros
. 2012 Sep;
12(2):183.
PMID: 22939519
No abstract available.